{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:55:57Z","timestamp":1790646957576,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12149-026-02233-w","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:25:49Z","timestamp":1780053949000},"page":"1188-1196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of 18\u00a0F-FDG PET\/CT SUVmax values in evaluating treatment response in hormone receptor\u2013positive metastatic breast cancer patients receiving CDK4\/6 inhibitor therapy"],"prefix":"10.1007","volume":"40","author":[{"given":"Rahime Dilara","family":"\u00d6zbek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayd\u0131n","family":"Aytekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-2438","authenticated-orcid":false,"given":"Enes","family":"Yerdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Elboga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2233_CR1","unstructured":"Ferley J, Soerjomataram I, Ervik M. Cancer incidence and mortality worldwide. IARC CancerBase No; 2013."},{"issue":"1","key":"2233_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.12-1-20","volume":"12","author":"MJ Hayat","year":"2007","unstructured":"Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12(1):20\u201337.","journal-title":"Oncologist"},{"issue":"7","key":"2233_CR3","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2174\/1568009617666170330120452","volume":"17","author":"SL Sammons","year":"2017","unstructured":"Sammons SL, Topping DL, Blackwell KL, HR+. HER2-advanced breast cancer and CDK4\/6 inhibitors: mode of action, clinical activity, and safety profiles. Curr Cancer Drug Targets. 2017;17(7):637\u201349.","journal-title":"Curr Cancer Drug Targets"},{"issue":"4","key":"2233_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"S-A Im","year":"2019","unstructured":"Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307\u201316.","journal-title":"N Engl J Med"},{"issue":"20","key":"2233_CR5","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im S-A, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926\u201336.","journal-title":"N Engl J Med"},{"issue":"32","key":"2233_CR6","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638\u201346.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2233_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S-A, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425\u201339.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2233_CR8","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/annonc\/mdy012","volume":"29","author":"H Rugo","year":"2018","unstructured":"Rugo H, Di\u00e9ras V, Gelmon K, Finn R, Slamon D, Martin M, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018;29(4):888\u201394.","journal-title":"Ann Oncol"},{"issue":"1","key":"2233_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25\u201335.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2233_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2174\/1874471007666140515114956","volume":"7","author":"L Evangelista","year":"2014","unstructured":"Evangelista L, Rita Cervino A. Nuclear imaging and early breast cancer detection. Curr Radiopharmaceuticals. 2014;7(1):29\u201335.","journal-title":"Curr Radiopharmaceuticals"},{"issue":"2","key":"2233_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1634\/theoncologist.2014-0342","volume":"20","author":"O Humbert","year":"2015","unstructured":"Humbert O, Cochet A, Coudert B, Berriolo-Riedinger A, Kanoun S, Brunotte F, et al. Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist. 2015;20(2):94\u2013104.","journal-title":"Oncologist"},{"issue":"7","key":"2233_CR12","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1158\/1078-0432.CCR-07-0934","volume":"14","author":"K Ott","year":"2008","unstructured":"Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14(7):2012\u20138.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2233_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1470-2045(07)70244-9","volume":"8","author":"F Lordick","year":"2007","unstructured":"Lordick F, Ott K, Krause B-J, Weber WA, Becker K, Stein HJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8(9):797\u2013805.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2233_CR14","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.3390\/cancers12092480","volume":"12","author":"D de Melo Gagliato","year":"2020","unstructured":"de Melo Gagliato D, Buzaid C, Perez-Garcia A, Llombart JM, Cortes A. Cdk4\/6 inhibitors in hormone receptor-positive metastatic breast cancer: current practice and knowledge. Cancers. 2020;12(9):2480.","journal-title":"Cancers"},{"issue":"3","key":"2233_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor\u2013positive advanced breast cancer. N Engl J Med. 2015;373(3):209\u201319.","journal-title":"N Engl J Med"},{"issue":"10226","key":"2233_CR16","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817\u201327.","journal-title":"Lancet"},{"issue":"9","key":"2233_CR17","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1007\/s00259-017-3703-7","volume":"44","author":"CC Riedl","year":"2017","unstructured":"Riedl CC, Pinker K, Ulaner GA, Ong LT, Baltzer P, Jochelson MS, et al. Comparison of FDG-PET\/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2017;44(9):1428\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2233_CR18","doi-asserted-by":"crossref","unstructured":"Hildebrandt MG, Naghavi-Behzad M, Vogsen M, editors. A role of FDG-PET\/CT for response evaluation in metastatic breast cancer? Seminars in nuclear medicine. Elsevier; 2022.","DOI":"10.1053\/j.semnuclmed.2022.03.004"},{"issue":"3","key":"2233_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2967\/jnumed.121.263358","volume":"64","author":"M Vogsen","year":"2023","unstructured":"Vogsen M, Harbo F, Jakobsen NM, Nissen HJ, Dahlsgaard-Wallenius SE, Gerke O, et al. Response monitoring in metastatic breast Cancer: a prospective study comparing 18F-FDG PET\/CT with conventional CT. J Nucl Med. 2023;64(3):355\u201361.","journal-title":"J Nucl Med"},{"issue":"5","key":"2233_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.remnie.2023.04.001","volume":"42","author":"H \u00d6nner","year":"2023","unstructured":"\u00d6nner H, Eren O\u00d6, K\u00f6rez MK, Yilmaz F, Gedik GK. Comparison of prognostic value of different metabolic response criteria determined by PET\/CT in patients with metastatic breast cancer under CDK 4\/6 inhibitor treatment. Revista Espa\u00f1ola de Med Nuclear e Imagen Mol (English Edition). 2023;42(5):319\u201324.","journal-title":"Revista Espa\u00f1ola de Med Nuclear e Imagen Mol (English Edition)"},{"key":"2233_CR21","doi-asserted-by":"publisher","first-page":"1193174","DOI":"10.3389\/fonc.2023.1193174","volume":"13","author":"A Annovazzi","year":"2023","unstructured":"Annovazzi A, Rea S, Maccora D, Pizzuti L, Ferretti G, Vici P, et al. Prognostic value of [18F]-FDG PET\/CT in patients with meta-static breast cancer treated with cyclin-dependent inhibitors. Front Oncol. 2023;13:1193174.","journal-title":"Front Oncol"},{"issue":"10","key":"2233_CR22","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.21873\/anticanres.15986","volume":"42","author":"H Ozawa","year":"2022","unstructured":"Ozawa H, Higuchi T, Fujimoto Y, Bun A, Fukui R, Kanaoka H, et al. Total lesion glycolysis levels as predictive indicators in patients with metastatic and recurrent breast cancer undergoing endocrine therapy with or without CDK4\/6 inhibitor. Anticancer Res. 2022;42(10):4813\u201324.","journal-title":"Anticancer Res"},{"issue":"7\u20138","key":"2233_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000516422","volume":"44","author":"R Seifert","year":"2021","unstructured":"Seifert R, K\u00fcper A, Tewes M, Heuschmid M, Welt A, Fendler WP, et al. [18F]-Fluorodeoxyglucose positron emission tomography\/CT to assess the early metabolic response in patients with hormone receptor-positive HER2-negative metastasized breast cancer treated with cyclin-dependent 4\/6 kinase inhibitors. Oncol Res Treat. 2021;44(7\u20138):400\u20137.","journal-title":"Oncol Res Treat"},{"issue":"3","key":"2233_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12149-018-01323-8","volume":"33","author":"S Taralli","year":"2019","unstructured":"Taralli S, Lorusso M, Scolozzi V, Masiello V, Marazzi F, Calcagni ML. Response evaluation with 18F-FDG PET\/CT in metastatic breast cancer patients treated with Palbociclib: First experience in clinical practice. Ann Nucl Med. 2019;33(3):193\u2013200.","journal-title":"Ann Nucl Med"},{"issue":"6","key":"2233_CR25","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/jmri.25112","volume":"43","author":"B Karan","year":"2016","unstructured":"Karan B, Pourbagher A, Torun N. Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography\/computed tomography in breast cancer: Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors. J Magn Reson Imaging. 2016;43(6):1434\u201344.","journal-title":"J Magn Reson Imaging"},{"issue":"13","key":"2233_CR26","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(14)70475-9","volume":"15","author":"B Coudert","year":"2014","unstructured":"Coudert B, Pierga J-Y, Mouret-Reynier M-A, Kerrou K, Ferrero J-M, Petit T, et al. Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. Lancet Oncol. 2014;15(13):1493\u2013502.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2233_CR27","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1200\/JCO.2013.54.0518","volume":"32","author":"IA Mayer","year":"2014","unstructured":"Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2014;32(12):1202\u20139.","journal-title":"J Clin Oncol"},{"key":"2233_CR28","doi-asserted-by":"publisher","first-page":"1454844","DOI":"10.3389\/fonc.2024.1454844","volume":"14","author":"M Kubeczko","year":"2024","unstructured":"Kubeczko M, Polakiewicz-Gilowska A, D\u2019Amico A, Chraba\u0144ski O, \u015awiderska K, Chmielik E, et al. The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4\/6 inhibitors in the second-line setting. Front Oncol. 2024;14:1454844.","journal-title":"Front Oncol"},{"key":"2233_CR29","doi-asserted-by":"publisher","first-page":"S643","DOI":"10.1016\/j.annonc.2022.07.269","volume":"33","author":"E Agostinetto","year":"2022","unstructured":"Agostinetto E, De Angelis C, Brand\u00e3o M, Flamen P, Piccart M, Azambuja E, et al. 230P Early metabolic response by FDG-PET scan predicts survival in patients with metastatic breast cancer receiving CDK4\/6 inhibitors: Preliminary results from the PUCCINI study. Ann Oncol. 2022;33:S643.","journal-title":"Ann Oncol"},{"key":"2233_CR30","unstructured":"Kumar A. Response evaluation with 18F FDG PET CT in hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (HR+\/HER2\u2013) advanced metastatic breast cancer (mBC) treated with cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitors plus endocrine treatment. Soc Nuclear Med; 2021."},{"issue":"5","key":"2233_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.remnie.2023.04.001","volume":"42","author":"H \u00d6nner","year":"2023","unstructured":"\u00d6nner H, Eren O\u00d6, K\u00f6rez MK, Yilmaz F, Kara Gedik G. Comparison of prognostic value of different metabolic response criteria determined by PET\/CT in patients with metastatic breast cancer under CDK 4\/6 inhibitor treatment. Revista Espa\u00f1ola de Med Nuclear e Imagen Mol (English Edition). 2023;42(5):319\u201324.","journal-title":"Revista Espa\u00f1ola de Med Nuclear e Imagen Mol (English Edition)"},{"key":"2233_CR32","doi-asserted-by":"publisher","first-page":"103806","DOI":"10.1016\/j.breast.2024.103806","volume":"78","author":"D Groheux","year":"2024","unstructured":"Groheux D, Vaz SC, Poortmans P, Mann RM, Ulaner GA, Cook GJR, et al. Role of [18F]FDG PET\/CT in patients with invasive breast carcinoma of no special type: literature review and comparison between guidelines. Breast. 2024;78:103806. https:\/\/doi.org\/10.1016\/j.breast.2024.103806.","journal-title":"Breast"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02233-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02233-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02233-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:04:06Z","timestamp":1790643846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02233-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2233"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02233-w","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No potential conflicts of interest were disclosed by the authors.","order":1,"name":"Ethics","label":"Conflicts of Interest \/ Competing Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived by the Ethics Committee due to the retrospective nature of the study.","order":2,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}